NCT06204835RecruitingPhase 1
ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery
ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery of HCC Patients
Source: ClinicalTrials.gov · Last updated 22 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In this study, the investigators will detect hepatocellular carcinoma lesions using fluoescence imaging with ITGA6 targeting probes during tumor resection surgery. The aim is to evaluate wether intraoperative fluorescence imaging targeting ITGA6 can help to improve the detction effect of hepatocellular carcinoma, and finally help the accurate surgical resection. The main purposes of this study include: 1. To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the ITGA6 targeting probe. 2. To validate the safety and effectiveness of the proposed ITGA6 targeting probes for clinical application.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 3 Jan 2024
- Start date
- 7 Jan 2024
- Primary completion date
- 31 Dec 2034
- Lead sponsor
- Institute of Automation, Chinese Academy of Sciences
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06204835
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 90
- From 7 Jan 2024 to the primary completion date, 31 Dec 2034
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergic to Cy7.
- Another malignant tumor was found.
- Undesirable function of heart, lung, kidney, or any other organs.
Other
- Enrolled in other trials in the past 3 months.
- Unable to tolerate a hepatectomy.
- The researchers considered inappropriate to be included.
Who the study is looking for
- Patients who have been diagnosed with hepatocellular carcinoma.
- Planned to receive hepatectomy.
- Liver function Child-Pugh A.
- ITGA6 was validated highly expressed preoperatively.
- Aged 18 to 80, and the expected lifetime is longer than 6 months.
- Approved to sign the informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guangdong Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
| Sichuan Coordinator of this site? Confirm its status | Luzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.